Scholar Rock Holding (SRRK) Research & Development (2017 - 2026)

Scholar Rock Holding's (SRRK) quarterly Research & Development came in at $51.8 million in Q1 2026, up 6.44% year-on-year from $48.7 million in Q1 2025, and up 10.54% quarter-over-quarter from $46.9 million in Q4 2025.

Scholar Rock Holding (SRRK) Research & Development (2017 - 2026) Analysis & Trends

Scholar Rock Holding's Research & Development history runs 10 years deep, the most recent figure standing at $51.8 million for Q1 2026.

  • On a quarterly basis, Research & Development rose 6.44% year-over-year to $51.8 million in Q1 2026; TTM through Mar 2026 was $211.6 million, a 11.28% increase from a year earlier, with the FY2025 full-year figure at $208.4 million, up 12.95% from the prior year.
  • Research & Development improved to $51.8 million in Q1 2026 per SRRK's latest filing, from $46.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $62.4 million in Q2 2025 and bottomed at $26.9 million in Q2 2023.
  • The 5-year median for Research & Development is $42.4 million (2024), against an average of $40.7 million.
  • Across the five-year window, Research & Development slipped 16.23% in 2023 and soared 60.59% in 2024, its largest moves.
  • Year by year, Research & Development stood at $29.6 million in 2022, then gained by 18.06% to $35.0 million in 2023, then soared by 44.06% to $50.4 million in 2024, then fell by 6.93% to $46.9 million in 2025, then climbed by 10.54% to $51.8 million in 2026.
  • Per Business Quant, the three latest SRRK Research & Development figures stand at $51.8 million (Q1 2026), $46.9 million (Q4 2025), and $50.5 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -17.94 Mn
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - 1.46 Mn
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 541.22 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 961.60 Mn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 1.54 Bn
7 Belite Bio 61.40 Bn 61.40 Bn - 15.66 Mn
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -443.00 Mn
9 Revolution Medicines 37.37 Bn 37.37 Bn - 343.97 Mn
10 Scholar Rock Holding 6.10 Bn 6.10 Bn - 51.81 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 51.81 Mn
Dec 31, 2025 46.88 Mn
Sep 30, 2025 50.49 Mn
Jun 30, 2025 62.40 Mn
Mar 31, 2025 48.68 Mn
Dec 31, 2024 50.37 Mn
Sep 30, 2024 48.72 Mn
Jun 30, 2024 42.37 Mn
Mar 31, 2024 43.09 Mn
Dec 31, 2023 34.96 Mn
Sep 30, 2023 30.34 Mn
Jun 30, 2023 26.87 Mn
Mar 31, 2023 29.74 Mn
Dec 31, 2022 29.61 Mn
Sep 30, 2022 33.39 Mn
Jun 30, 2022 32.07 Mn
Mar 31, 2022 29.37 Mn
Dec 31, 2021 29.05 Mn
Sep 30, 2021 31.27 Mn
Jun 30, 2021 25.60 Mn